

# International Nonproprietary Names for Pharmaceutical Substances (INN)

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 68 Proposed INN not later than 30 June 1993**.

## Proposed International Nonproprietary Names: List 68


*Lists of proposed (1–65) and recommended (1–31) international nonproprietary names can be found in Cumulative List No. 8, 1992.*

*Proposed International  
Nonproprietary Name  
(Latin, English)*

*Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\**

alestramustinum  
alestramustine

estradiol 3-[bis(2-chloroethyl)carbamate], 17-ester with L-alanine  
 $C_{26}H_{36}Cl_2N_2O_4$  139402-18-9 *antineoplastic*



alglucerasum  
alglucerase

glucosylceramidase (human placenta isoenzyme protein moiety reduced)  
 $C_{2532}H_{3854}N_{672}O_{711}S_{16}$  143003-46-7 *glucocerebrosidase*  
(for non-glycosylated protein)


**\*Action and Use:** *The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will be neither revised nor included in the Cumulative Lists of INNs.*

Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

alovudinum  
alovudine

3'-deoxy-3'-fluorothymidine  
 $C_{10}H_{13}FN_2O_4$  25526-93-6 *antiviral*



altumomabum  
altumomab


immunoglobulin G 1 (mouse monoclonal ZCE025 anti-human antigen CEA),  
disulfide with mouse monoclonal ZCE025 light chain, dimer  
*radiodiagnostic monoclonal antibody*

ardeparinum natricum  
ardeparin sodium

Sodium salt of depolymerized heparin obtained by peroxide degradation (at elevated temperature) of heparin from pork intestinal mucosa; the end chain structure appears to be the same as the starting material with no unusual sugar residues present; the low molecular weight heparin produced differs from the starting material in molecular weight only; the average relative molecular mass range is 5,500 to 6,500 daltons, 98 per cent of which ranging between 2,000 and 15,000; the degree of sulfation is approximately 2,7 per disaccharidic unit.  
*anticoagulant*

atrinositolum  
atrinositol

D-*myo*-inositol 1,2,6-tris(dihydrogen phosphate)  
 $C_6H_{15}O_{15}P_3$  28841-62-5 *neuropeptide antagonist*




avicationinum  
avicationin

1-butyric acid-2-L-alanine-3-L-serine-7-(L-2-aminobutyric acid)-26-L-aspartic acid-  
27-L-valine-29-L-alaninecalcitonin (salmon)  
 $C_{147}H_{243}N_{41}O_{46}$  103451-84-9 *calcium regulator*


azasetronum  
azasetron

(±)-6-chloro-3,4-dihydro-4-methyl-3-oxo-N-3-quinuclidinyl-2H-1,4-benzoxazine-8-  
carboxamide  
 $C_{17}H_{20}ClN_3O_3$  123040-69-7 *serotonin receptor antagonist*




berefrinum  
berefriine

*m*-[(2*R*,5*R*)-2-*tert*-butyl-3-methyl-5-oxazolidinyl]phenol mixture with *m*-[(2*S*,5*R*)-2-*tert*-butyl-3-methyl-5-oxazolidinyl]phenol  
C<sub>14</sub>H<sub>21</sub>NO<sub>2</sub> 105567-83-7 *mydriatic*




besigomsinum  
besigomsin

(+)-(6*S*,7*S*, *biar-R*)-5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-*f*][1,3]benzodioxol-6-ol  
C<sub>23</sub>H<sub>28</sub>O<sub>7</sub> 58546-54-6 *hepatoprotectant*




bizelesinum  
bizelesin

1,3-bis[2-[(*S*)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-*b*:4,3-*b'*]dipyrrol-3(2*H*)-yl]carbonyl]indol-5-yl]urea  
C<sub>43</sub>H<sub>35</sub>Cl<sub>2</sub>N<sub>8</sub>O<sub>8</sub> 129655-21-6 *antineoplastic*




cefcapenum  
cefcapepe

(6*R*,7*R*)-7-[(*Z*)-2-(2-amino-4-thiazolyl)-2-pentenamido]-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, carbamate (ester)  
C<sub>17</sub>H<sub>19</sub>N<sub>5</sub>O<sub>6</sub>S<sub>2</sub> 135889-00-8 *antibiotic*



cetefloxacinum  
cetefloxacin

(-)-7-[(2*S*,3*R*)-3-amino-2-methyl-1-azetidiny]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid  
C<sub>20</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> 141725-88-4 *antibacterial*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


cilansetronum  
cilansetron

(-)-(R)-5,6,9,10-tetrahydro-10-[(2-methylimidazol-1-yl)methyl]-4H-pyrindo[3,2,1-*jk*]carbazol-11(8*H*)-one  
C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O 120635-74-7 serotonin receptor antagonist




cladribinum  
cladribine

2-chloro-2'-deoxyadenosine  
C<sub>10</sub>H<sub>12</sub>ClN<sub>5</sub>O<sub>3</sub> 4291-63-8 antileukaemic




clinprostium  
cliprost

(+)-methyl (3*aS*,5*R*,6*R*,6*aS*)-1,3*a*,4,5,6,6*a*-hexahydro-5-hydroxy-6-[(*E*)-(3*S*)-3-hydroxy-1-octenyl]-2-pentalevalerate  
C<sub>22</sub>H<sub>36</sub>O<sub>4</sub> 88931-51-5 platelet aggregation inhibitor




dezinamidum  
dezinamide

3-[( $\alpha,\alpha,\alpha$ -trifluoro-*m*-tolyl)oxy]-1-azetidincarboxamide  
C<sub>11</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 91077-32-6 anticonvulsant




dimiracetamum  
dimiracetam

( $\pm$ )-dihydro-1*H*-pyrrolo[1,2-*a*]imidazole-2,5(3*H*,6*H*)-dione  
C<sub>6</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub> 126100-97-8 nootropic



duloxetineum  
duloxetine

(+)-(S)-N-methyl- $\gamma$ -(1-naphthyl)oxy)-2-thiophenepropylamine  
C<sub>18</sub>H<sub>19</sub>NOS 116539-59-4 antidepressant




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


ecadotrilum  
ecadotril

*N*-[(*S*)- $\alpha$ -(mercaptomethyl)hydrocinnamoyl]glycine, benzyl ester, acetate (ester)  
C<sub>21</sub>H<sub>23</sub>NO<sub>4</sub>S 112573-73-6 *endopeptidase inhibitor*




enadolinum  
enadoline

*N*-methyl-*N*-[(5*R*,7*S*,8*S*)-7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-4-benzofuranacetamide  
C<sub>24</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub> 124378-77-4 *analgesic*




enazadremum  
enazadrem

4,6-dimethyl-2-[(6-phenylhexyl)amino]-5-pyrimidinol  
C<sub>18</sub>H<sub>25</sub>N<sub>3</sub>O 107361-33-1 *antipsoriatic*



fialuridinum  
fialuridine

1-(2-deoxy-2-fluoro- $\beta$ -D-arabinofuranosyl)-5-iodouracil  
C<sub>9</sub>H<sub>10</sub>FIN<sub>2</sub>O<sub>5</sub> 69123-98-4 *antiviral*



ganefromycinum  
ganefromycin

An antibiotic produced by *Streptomyces lydicus*.  
Ganefromycin is a complex antibiotic with two major components:  $\alpha$  and  $\beta$ .

component  $\alpha$



(2*E*,4*E*,6*E*)-7-[(2*R*\*,3*R*\*,5*R*\*)-5-[7-[(3*E*,5*E*)-3-[[*O*-2,6-dideoxy-3-*O*-methyl- $\alpha$ -lyxo-hexopyranosyl-(1 $\rightarrow$ 4)-*O*-2,6-dideoxy-3-*O*-methyl- $\beta$ -ribo-hexopyranosyl-(1 $\rightarrow$ 4)-2,6-dideoxy-3-*O*-methyl- $\alpha$ -lyxo-hexopyranosyl]oxy]-2-[(2*S*\*,3*S*\*,4*S*\*,6*R*\*)-tetrahydro-2,3,4-trihydroxy-5,5-dimethyl-6-[(1*E*,3*Z*)-1,3-pentadienyl]-2*H*-pyran-2-yl]propionamido]-2-methoxy-1,3-dimethyl-3,5-heptadienyl]tetrahydro-3-hydroxy-2-furyl]-2,4,6-heptatrienoic acid, 2<sup>3</sup>-phenylacetate  
114451-31-9

component  $\beta$

(2*E*,4*E*,6*E*)-7-[(2*R*\*,3*R*\*,5*R*\*)-5-[7-[(3*E*,5*E*)-3-[[*O*-2,6-dideoxy-3-*O*-methyl- $\alpha$ -lyxo-hexopyranosyl-(1 $\rightarrow$ 4)-*O*-2,6-dideoxy-3-*O*-methyl- $\beta$ -ribo-hexopyranosyl-(1 $\rightarrow$ 4)-2,6-dideoxy-3-*O*-methyl- $\alpha$ -lyxo-hexopyranosyl]oxy]-2-[(2*S*\*,3*S*\*,4*S*\*,6*R*\*)-tetrahydro-2,3,4-trihydroxy-5,5-dimethyl-6-[(1*E*,3*Z*)-1,3-pentadienyl]-2*H*-pyran-2-yl]propionamido]-2-methoxy-1,3-dimethyl-3,5-heptadienyl]tetrahydro-3-hydroxy-2-furyl]-2,4,6-heptatrienoic acid, 2<sup>4</sup>-phenylacetate  
114451-30-8


C<sub>65</sub>H<sub>95</sub>NO<sub>21</sub> (empirical molecular formula)

growth stimulant;  
antibacterial (vet.)




glemanserinum  
glemanserin

( $\pm$ )-1-phenethyl- $\alpha$ -phenyl-4-piperidinemethanol  
C<sub>20</sub>H<sub>25</sub>NO      107703-78-6      serotonin receptor antagonist



grepafloxacinum  
grepafloxacin

( $\pm$ )-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid  
C<sub>19</sub>H<sub>22</sub>FN<sub>3</sub>O<sub>3</sub>      119914-60-2      antibacterial




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


gusperimus  
gusperimus

(±)-N-[[[4-[(3-aminopropyl)amino]butyl]carbonyl]hydroxymethyl]-7-guanidinoheptanamide  
C<sub>17</sub>H<sub>37</sub>N<sub>7</sub>O<sub>3</sub> 104317-84-2 immunosuppressant




icodextrinum  
icodextrin

dextrin, having more than 85% of its molecules with molecular masses between 1640 and 45000 with a claimed-average molecular mass of approximately 20000  
[C<sub>6</sub>H<sub>12</sub>O<sub>6</sub>]<sub>n</sub> 9004-53-9 peritoneal dialysis fluid




icoduline  
icodulinum

6-(2-thiazolylamino)-*m*-cresol  
C<sub>10</sub>H<sub>10</sub>N<sub>2</sub>OS 138511-81-6 non steroidal anti-inflammatory




idoxifenum  
idoxifene

1-[2-[*p*-[(*E*-β-ethyl-α-(*p*-iodophenyl)styryl]phenoxy]ethyl]pyrrolidine  
C<sub>28</sub>H<sub>30</sub>INO 116057-75-1 antineoplastic




igmesinum  
igmesine

(+)-α-[(*E*-cinnamyl)]-N-(cyclopropylmethyl)-α-ethyl-N-methylbenzylamine  
C<sub>25</sub>H<sub>29</sub>N 140850-73-3 σ opiate receptor antagonist




iobitridolum  
iobitridol

*N,N'*-bis(2,3-dihydroxypropyl)-5-[2-(hydroxymethyl)hydracrylamido]-2,4,6-triiodo-*N,N'*-dimethylisophthalamide  
C<sub>20</sub>H<sub>28</sub>I<sub>3</sub>N<sub>3</sub>O<sub>9</sub> 136949-58-1 contrast medium




itasetronum  
itasetron

2-oxo-*N*-1 $\alpha$ ,5 $\alpha$ -*H*-tropan-3 $\alpha$ -yl-1-benzimidazole-1-carboxamide  
C<sub>16</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> 123258-84-4 serotonin receptor antagonist




leminoprazolum  
leminoprazole

( $\pm$ )-2-[[*o*-(isobutylmethylamino)benzyl]sulfinyl]benzimidazole  
C<sub>19</sub>H<sub>23</sub>N<sub>3</sub>OS 104340-86-5 antiulcer




levosimendanum  
levosimendan

mesoxalonitrile (-)-[*p*[(*R*)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazone  
C<sub>14</sub>H<sub>12</sub>N<sub>6</sub>O 141505-33-1 cardiac stimulant



lomerizinum  
lomerizine

1-[bis(*p*-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine  
C<sub>27</sub>H<sub>30</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub> 101477-55-8 cerebral vasodilator




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


losoxantrone  
losoxantrone

7-hydroxy-2-[[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthra[1,9-*cd*]pyrazol-6(2*H*)-one  
C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub> 88303-60-0 *antineoplastic*



monatepilum  
monatepil

(±)-*N*-(6,11-dihydrodibenzo[*b,e*]thiepin-11-yl)-4-(*p*-fluorophenyl)-1-piperazinebutyramide  
C<sub>28</sub>H<sub>30</sub>FN<sub>3</sub>OS 132019-54-6 *calcium channel blocker*




nasaruplasum  
nasaruplase

prourokinase (enzyme-activating) (human clone pA3/pD2/pF1 protein moiety)  
C<sub>2031</sub>H<sub>3121</sub>N<sub>585</sub>O<sub>601</sub>S<sub>31</sub> 99821-44-0 *enzyme*


niravolinum  
niravoline

*N*-methyl-2-(*m*-nitrophenyl)-*N*-[(1*S*,2*S*)-2-(1-pyrrolidinyl)-1-indanyl]acetamide  
C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> 130610-93-4 *diuretic*




odapipamum  
odapipam

(+)-(*S*)-8-chloro-5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-1*H*-3-benzazepin-7-ol  
C<sub>19</sub>H<sub>20</sub>ClNO<sub>2</sub> 131796-63-9 *dopamine D<sub>1</sub> receptor antagonist*



orbifloxacinum  
orbifloxacin

1-cyclopropyl-7-(*cis*-3,5-dimethyl-1-piperazinyl)-5,6,8-trifluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid  
C<sub>19</sub>H<sub>20</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> 113617-63-3 *antibacterial*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


osateronum  
osaterone

(+)-6-chloro-17-hydroxy-2-oxapregna-4,6-diene-3,20-dione  
C<sub>20</sub>H<sub>25</sub>ClO<sub>4</sub> 105149-04-0 *antiandrogen, progestogen*




paclitaxelum  
paclitaxel

(2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5*H*-cyclodeca[3,4]benz[1,2-*b*]oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2*R*,3*S*)-*N*-benzoyl-3-phenylisoserine  
C<sub>47</sub>H<sub>51</sub>NO<sub>14</sub> 33069-62-4 *antineoplastic*




pidobenzonum  
pidobenzone

5-oxo-L-proline, *p*-hydroxyphenyl ester  
C<sub>11</sub>H<sub>11</sub>NO<sub>4</sub> 138506-45-3 *melanine synthesis inhibitor*



ramorelixum  
ramorelix

1-[*N*-acetyl-3-(2-naphthyl)-*D*-alanyl-*p*-chloro-*D*-phenylalanyl-*D*-tryptophyl-L-seryl-L-tyrosyl-*O*-(6-deoxy- $\alpha$ -L-mannopyranosyl)-*D*-seryl-L-leucyl-L-arginyl-L-prolyl]semicarbazide  
C<sub>74</sub>H<sub>95</sub>ClN<sub>16</sub>O<sub>18</sub> 136639-71-9 *lutinizing-hormone-releasing-hormone inhibitor*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


raxofelastum  
raxofelast

(±)-2,3-dihydro-5-hydroxy-4,6,7-trimethyl-2-benzofuranacetic acid, acetate  
C<sub>15</sub>H<sub>18</sub>O<sub>5</sub> 128232-14-4 *antiasthmatic, anti-inflammatory*




safironilum  
safironil

*N,N'*-bis(3-methoxypropyl)-2,4-pyridinedicarboxamide  
C<sub>15</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub> 134377-69-8 *collagen inhibitor*




sameridinum  
sameridine

*N*-ethyl-1-hexyl-*N*-methyl-4-phenylisonipecotamide  
C<sub>21</sub>H<sub>34</sub>N<sub>2</sub>O 143257-97-0 *analgesic, local anaesthetic*




sanguinarii chloridum  
sanguinarium chloride

sanguinarine chloride or 13-methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-*l*]-phenanthridinium chloride  
C<sub>20</sub>H<sub>14</sub>ClNO<sub>4</sub> 5578-73-4 *anti-inflammatory; antimicrobial; antifungal*




sebriplatinum  
sebriplatin

(+)-*cis*-(1,1-cyclobutanedicarboxylato)[(2*R*)-2-methyl-1,4-butanediamine-*N,N'*]platinum  
C<sub>11</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>Pt 110172-45-7 *antineoplastic*



sepimostatium  
sepimostat

6-amidino-2-naphthyl *p*-(2-imidazolin-2-ylamino)benzoate  
C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub> 103926-64-3 *protease inhibitor*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

siratiazemum  
siratiazem

(+)-(2*S*,3*S*)-2,3-dihydro-3-hydroxy-5-[2-(isopropylmethylamino)ethyl]-2-(*p*-methoxyphenyl)-1,5-benzothiazepin-4(5*H*)-one acetate (ester)  
C<sub>24</sub>H<sub>30</sub>N<sub>2</sub>O<sub>4</sub>S 138778-28-6 *antianginal, antihypertensive*




sonerminum  
sonermin

3-157-tumor necrosis factor (human)  
C<sub>767</sub>H<sub>1204</sub>N<sub>210</sub>O<sub>229</sub>S<sub>2</sub> 144916-42-7 *antineoplastic*


sulopenemum  
sulopenem

(5*R*,6*S*)-6-[(1*R*)-1-hydroxyethyl]-7-oxo-3-[[[(3*S*)-tetrahydro-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (*R*)-*S*-oxide  
C<sub>12</sub>H<sub>15</sub>NO<sub>5</sub>S<sub>3</sub> 120788-07-0 *antibacterial*




tallimustinum  
tallimustine

*N*'-(2-amidinoethyl)-4-[*p*-bis(2-chloroethyl)amino]benzamido]-1,1',1''-trimethyl-*N*,4',*N*',4''-ter[pyrrole-2-carboxamide]  
C<sub>32</sub>H<sub>38</sub>Cl<sub>2</sub>N<sub>10</sub>O<sub>4</sub> 115308-98-0 *antineoplastic*



tarazepidum  
tarazepide

(-)-*N*-[(*S*)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1*H*-1,4-benzodiazepin-3-yl]-5,6-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinoline-2-carboxamide  
C<sub>28</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> 141374-81-4 *cholecystokinin inhibitor*






Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


troglitazonum  
troglitazone

(±)-*all-rac*-5-[*p*-[(6-hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy]benzyl]-2,4-thiazolidinedione  
C<sub>24</sub>H<sub>27</sub>NO<sub>5</sub>S 97322-87-7 hypoglycaemic

1:1 mixture of




with




valsartanum  
valsartan

*N*-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]-*N*-valeryl-L-valine  
C<sub>24</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub> 137862-53-4 antihypertensive



zamifenacinum  
zamifenacin

(*R*)-3-(diphenylmethoxy)-1-[3,4-(methylenedioxy)phenetyl]piperidine  
C<sub>27</sub>H<sub>29</sub>NO<sub>3</sub> 127308-82-1 muscarin receptor antagonist



**AMENDMENTS  
TO PREVIOUS LISTS**

Chronicle of the World Health Organization Vol. 7, No. 10, 1953

**Proposed International Nonproprietary Names (Prop. INN): List 1**

p. 304	<i>delete</i>	<i>insert</i>
	corticotrophinum corticotrophin	corticotropinum corticotropin

Chronicle of the World Health Organization Vol. 12, No. 3, 1958

**Proposed International Nonproprietary Names (Prop. INN): List 6**

p. 103	<i>delete</i>	<i>insert</i>
	corticotrophinum zinci hydroxydum corticotrophin zinc hydroxide	corticotropinum zinci hydroxydum corticotropin zinc hydroxide

Supplement to WHO Chronicle Vol. 37, No. 5, 1983

**Proposed International Nonproprietary Names (Prop. INN): List 50**

p. 14	icospiramidum icospiramide	<i>replace the chemical name by the following:</i> 8-[ <i>cis</i> -4-cyano-4-( <i>p</i> -fluorophenyl)cyclohexyl]-1-( <i>p</i> -fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]decane-3-acetamide
-------	-------------------------------	---

WHO Drug Information, Vol. 4, No. 2, 1990


**Proposed International Nonproprietary Names (Prop. INN): List 63**

p. 4	<i>delete</i>	<i>insert</i>
	docetaxolum docetaxol	docetaxelum docetaxel

WHO Drug Information, Vol. 4, No. 4, 1990

**Proposed International Nonproprietary Names (Prop. INN): List 64**

p. 13	leuciglumerum leuciglumer	<i>replace the molecular formula and the graphic formula by the following:</i> (C <sub>5</sub> H <sub>13</sub> NO <sub>2</sub> · C <sub>6</sub> H <sub>11</sub> NO <sub>2</sub> ) <sub>n</sub>
-------	------------------------------	---



**Proposed International Nonproprietary Names (Prop. INN): List 66**

- |      |                                   |   |
|------|-----------------------------------|---|
| p. 4 | dexfosfoferinum<br>dexfosfoferine | <i>replace the chemical name by the following:</i><br>(+)-L-serine dihydrogen phosphate (ester) |
| p. 6 | ilatreatidum<br>ilatreatide       | <i>include the following CAS registry number:</i><br>119719-11-8                                |

**Proposed International Nonproprietary Names (Prop. INN): List 67**

- |       |                          |   |
|-------|--------------------------|---|
| p. 9  | satumomabum<br>satumomab | <i>include the following CAS registry number:</i><br>144058-40-2  |
| p. 12 | limaprostum<br>limaprost | <i>replace the chemical name by the following:</i><br>(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonyl]-5-oxocyclopentyl]-2-heptenoic acid |

**Procedure and Guiding Principles**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN lists only.